Tackling Emerging Co-Infections

点击翻译按钮获取中文摘要

Humans are continuously exposed to multiple pathogens yet, with the exception of a few well defined coinfection scenarios (HIV and tuberculosis for example), relatively little is known about the impact of co-infections on morbidity and mortality. There is growing evidence indicating that co-infections are common, exacerbate disease severity and can considerably worsen outcome (Influenza or COVID-19 associated Aspergillus infection for example). Co-infections with drug-resistant pathogens have shown to add another layer of complexity with high case-fatality rates. Our aim is to integrate and exploit the expertise of four Centres that are tackling the major pathogen groups [viruses, bacteria, fungi and parasites] to promote UK-wide research on the pathophysiological impact and mechanistic basis of disease in co-infections.